Healthcare Feb 05, 2021 02:07 PM (GMT+8) · EqualOcean
EUROHEALTH, February 5 - the State Drug Administration (nmpa) has approved the first-line clinical trial of the company's independently developed Bruton tyrosine kinase (Btk) inhibitor, orbotinib, combined with R-CHOP, in the treatment of mantle cell lymphoma (MCL), a biomedical company, announced today. Obutinib is a class 1 innovative drug independently developed by ncjh. It is a new Btk inhibitor for the treatment of lymphoma and autoimmune diseases. On December 25, 2020, obutinib was approved by nmpa for the treatment of relapsed / refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients and relapsed / refractory MCL patients. On December 31, 2020, obutinib was awarded orphan drug designation by the US Food and Drug Administration for the treatment of mantle cell lymphoma (MCL).